| Literature DB >> 23758816 |
Diederike Geelhoed1, Yves Lafort, Élder Chissale, Baltazar Candrinho, Olivier Degomme.
Abstract
BACKGROUND: The follow-up of HIV-exposed infants remains a public health challenge in many Sub-Saharan countries. Just as integrated antenatal and maternity services have contributed to improved care for HIV-positive pregnant women, so too could integrated care for mother and infant after birth improve follow-up of HIV-exposed infants. We present results of a study testing the viability of such integrated care, and its effects on follow-up of HIV-exposed infants, in Tete Province, Mozambique.Entities:
Mesh:
Year: 2013 PMID: 23758816 PMCID: PMC3679935 DOI: 10.1186/1472-6963-13-207
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
List of variables from MCH activities collected monthly in the participant health care facilities
| 1 Number of pregnant women diagnosed with HIV in antenatal care | 1 Number of live newborns from HIV-positive women giving birth in the health care facility (or at home but presented within 48h after birth) |
| 2 Number of HIV-positive pregnant women starting antiretroviral prophylaxis or treatment in antenatal care | 2 Number of live newborns from HIV-positive women giving birth in the health care facility (or at home but presented within 48h after birth) who received antiretroviral prophylaxis |
| 3 Number of HIV-positive women giving birth in the health care facility | 3 Number of HIV-exposed infants registered in the follow-up programme (per age group) |
| 4 Number of HIV-positive women giving birth in the health care facility who received antiretroviral prophylaxis or treatment at childbirth | 4 Number of HIV-exposed infants who visited for follow-up (per sex, age group and nº of times visited) |
| 5 Number of childbirths of HIV-positive women with antiretroviral prophylaxis (or treatment) of both mother and newborn | 5 Number of HIV-exposed children tested for HIV (per sex, age group and type of test used) |
| 6 Number of women starting a modern contraceptive method (general and HIV-positive) | 6 Number of HIV-exposed children tested for HIV (per sex, age group and type of test used) who tested HIV-positive |
| 7 Number of women attended for post partum care (general and HIV-positive) | 7 Number of children vaccinated (per vaccine: BCG, DPT3, Measles) |
| 8 Number of women of reproductive age supplemented with Vitamin A | 8 Number of children supplemented with Vitamin A |
| 9 Number of women of reproductive age vaccinated for tetanus | 9 Number of children de-wormed |
Average number of monthly MCH consultations in intervention and control clinics, pre- and post-intervention
| Maternal health consultations* | 785 | 525 | 748 | 501 | 0.034 | 0.535 |
| Child health consultations** | 1355 | 857 | 1048 | 956 | 0.009 | 0.194 |
*Comprises women initiating family planning, postnatal care visits, Vit A supplements in postpartum women and tetanus vaccination in women of reproductive age.
**Comprises BCG, DTP3 and measles vaccinations, Vit A supplements and mebendazole presumptive treatment in children.
Time trends in number of monthly HIV follow-up visits during the 13 months post-intervention period
| HIV-exposed infants initiating follow-up visits | 76 | −0.023 | 0.104 | 1.15 | 0.015 |
| Follow-up visits by HIV-exposed infants | 76 | 0.121 | 0.038 | 0.96 | 0.262 |
| HIV tests in HIV-exposed infants | 76 | 0.052 | 0.305 | 0.96 | 0.362 |
Distribution of HIV-exposed infants with follow-up by age at registration and number of follow-up visits
| Unknown | 6.7% | 12.6% | 0.0% | 0.0% | ||
| 0-3 months | 50.5% | 72.4% | 50.6% | 75.7% | <0.001 | 0.394 |
| 4-6 months | 18.1% | 4.6% | 18.5% | 13.6% | 0.013 | 0.288 |
| 7-18 months | 24.8% | 10.3% | 30.9% | 10.7% | <0.001 | 0.741 |
| First visit | 40.0% | 19.5% | 30.1% | 33.9% | <0.001 | 0.011 |
| Second visit | 29.5% | 21.9% | 31.6% | 22.4% | 0.004 | 0.694 |
| Third visit | 13.7% | 17.4% | 16.9% | 14.1% | 0.655 | 0.557 |
| Fourth visit | 6.8% | 13.2% | 11.0% | 8.6% | 0.179 | 0.296 |
| Fifth or sixth visit | 5.3% | 18.1% | 8.1% | 10.9% | <0.001 | 0.037 |
| Seventh or more visit | 4.7% | 9.8% | 2.2% | 10.2% | <0.001 | 0.726 |
| 7-9 months | 20.0% | 48.6% | 22.9% | 25.0% | 0.028 | 0.092 |
| 10-12 months | 60.0% | 35.1% | 40.0% | 50.0% | 0.423 | 0.940 |
| >=13 months | 20.0% | 16.2% | 37.1% | 25.0% | 0.149 | 0.059 |
Effect of absence of staff, HIV testing commodities and PMTCT drugs on monthly MCH consultations in all clinics, post-intervention
| HIV-exposed infants starting follow-up visits | 67 | 0.20 | 0.200 |
| Any HIV tests in HIV-exposed infants | 69 | 0.06 | 0.027 |
| Serologic HIV tests in HIV-exposed infants | 69 | 0.10 | 0.030 |
| Pregnant women detected as HIV+ | 70 | 0.48 | 0.166 |
| Any HIV tests in HIV-exposed infants | 70 | 0.90 | 0.812 |
| Serologic HIV tests in HIV-exposed infants | 70 | 0.56 | 0.201 |
| HIV + pregnant women initiating PMTCT | 69 | 0.56 | 0.463 |
| HIV + women receiving PMTCT during childbirth | 69 | 0.32 | 0.196 |
| HIV-exposed infants receiving PMTCT at birth | 69 | 0.32 | 0.193 |